ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

T Koessler; M Alsina; D Arnold; I Ben-Aharon; M Collienne; M P Lutz; C Neuzillet; R Obermannova; M Peeters; F Sclafani; E Smyth; J W Valle; A D Wagner; L Wyrwicz; E Fontana; M Moehler

doi:10.1016/j.esmoop.2022.100392

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

ESMO Open. 2022 Apr;7(2):100392. doi: 10.1016/j.esmoop.2022.100392. Epub 2022 Feb 16.

Authors

T Koessler¹, M Alsina², D Arnold³, I Ben-Aharon⁴, M Collienne⁵, M P Lutz⁶, C Neuzillet⁷, R Obermannova⁸, M Peeters⁹, F Sclafani¹⁰, E Smyth¹¹, J W Valle¹², A D Wagner¹³, L Wyrwicz¹⁴, E Fontana¹⁵, M Moehler¹⁶

Affiliations

¹ Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. Electronic address: Thibaud.kossler@hcuge.ch.
² Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
³ Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany.
⁴ Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
⁵ Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
⁶ Caritasklinikum, Saarbrucken, Germany.
⁷ GI Oncology, Medical Oncology Department, Institut Curie Saint-Cloud, Versailles Saint Quentin University, Saint-Cloud, France.
⁸ Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno; Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
⁹ Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium.
¹⁰ Department of Medical Oncology, Institut Jules Bordet-Université Libre de Bruxelles (ULB), Brussels, Belgium.
¹¹ Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
¹² Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
¹³ Department of Oncology, Division of Medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
¹⁴ Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
¹⁵ Sarah Cannon Research Institute, London, UK.
¹⁶ Department of Internal Medicine, Johannes-Gutenberg University, Mainz, Germany.

Abstract

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Keywords: colorectal cancer; neuroendocrine tumours; oesophagus cancer; pancreatic cancer; stomach cancer.

Publication types

Congress
Research Support, Non-U.S. Gov't

MeSH terms

Gastrointestinal Neoplasms* / drug therapy
Humans
Immunotherapy
Medical Oncology*